Advisors Asset Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Advisors Asset Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,964	Closed	-$374K	–	1525
2022 Q2	$374K	Sell	4,964 -61	-1%	-$2.71K	0.01%	1023
2022 Q1	$135K	Sell	5,025 -1,627	-24%	-$54.7K	﹤0.01%	1313
2021 Q4	$317K	Sell	6,652 -156	-2%	-$6.97K	﹤0.01%	1118
2021 Q3	$452K	Buy	6,808 +777	+13%	+$55.4K	0.01%	1043
2021 Q2	$471K	Buy	6,031 +2,180	+57%	+$161K	0.01%	1017
2021 Q1	$364K	Buy	3,851 +1,280	+50%	+$152K	0.01%	1089
2020 Q4	$313K	Buy	+2,571	New	+$282K	0.01%	1101

Advisors Asset Management's TPTX Position: Q3 2022 in Review

Advisors Asset Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 4,964 shares — an estimated $374K sold.

Advisors Asset Management first reported a position in TPTX in Q4 2020 and held it in 7 quarters. The position peaked at $471K in Q2 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Advisors Asset Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Advisors Asset Management sold 4,964 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $374K.
Advisors Asset Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
Advisors Asset Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $471K in Q2 2021.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Advisors Asset Management's 13F filing for Q3 2022, filed 8 Nov 2022.